Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 30, 2026Journal of Clinical Oncology

A real-world study of RET fusion in patients with solid tumor.

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKaidiriye SetiwalidiXFXiao FuYYYu Yao

Discussion

Loading...

Member takes

Overview

Retrospective cohort study examines RET fusion impact on survival in solid tumors, suggesting treatment implications.

Key Points

  • This study aims to characterize clinical and molecular features of RET fusion-positive solid tumors and evaluate treatment outcomes.
  • Single-center retrospective cohort study at Xi'an Jiaotong University
  • Data collected from electronic medical records between 2016 and 2025
  • Survival analysis performed using Kaplan–Meier and Cox models.
  • 160 RET fusion-positive patients enrolled, median age 58, predominantly lung cancer cases.
  • Median overall survival: 48 months for lung cancer, not reached for thyroid cancer, 20 months for gastrointestinal tumors.
  • RET-TKIs showed longer progression-free survival compared to chemotherapy in both first-line and second-line.

Cite This Study

Setiwalidi et al. (2026) studied this question.

synapsesocial.com/papers/6a1a80550307b7850943246dhttps://doi.org/10.1200/jco.2026.44.16_suppl.e20678
View Full Paper
Ask AI
Bookmark
Share